Skip to main content
Caplight Logo









Autolomous

Autolomous

Private
LondonHealthcare & Life Scienceshttps://autolomous.com/

Last Round

Grant

Jun 12, 2023

Total Funding Raised

$2.13M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Autolomous is a software company that provides a digital manufacturing management platform for cell and gene therapy developers and manufacturers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Quality Management, Workflow Automation, Compliance

Business Model

B2B

Customer Profile

Subscription SaaS, Freemium

AI Layer

Application

Keywords

manufacturing execution systemMESadvanced therapy medicinal productsATMPelectronic batch recordseBRcell and gene therapyquality management systemQMSbiotech manufacturingpharma supply chaindigital manufacturingcGMP compliancelab informaticsbioprocessing softwarepharma tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autolomous Comparables

Compare Autolomous with similar companies based on industry and business-model similarity.

Autolomous comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TrakCel
86%
Leucine
78%
Apprentice
78%

Autolomous Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 12, 2023
Early FundingDec 27, 2022
GrantJul 27, 2021
DebtMay 4, 2021
SeedAug 5, 2020

Key People

Founding team and executive leadership

Alexander Seyf

Chief Executive Officer

Executive Team

Alexis Blain

Chief Technology Officer

Executive Team

Walid Fahme

Chief Operating Officer

Executive Team

Autolomous Investors

Notable investors and investment history

Autolomous investors
InvestorRounds
UKRI Innovate UKDebt, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 14, 2026

    Monthly visitors increased 86% MoM, reaching 4K.

  • Jan 6, 2026

    Monthly visitors increased 564% MoM, from 232 to 1.5K.

Autolomous Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Autolomous Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Autolomous's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range37
Year Founded2019
Last FundingJun 12, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?